A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DOMONSTRATE EFFECTIVENESS, IMMUNOGENICITY AND SAFETY OF GSK'S MENINGOCOCCAL GROUP B AND COMBINED ABCWY VACCINES WHEN ADMINISTERED TO HEALTHY ADOLESCENTS AND YOUNG ADULTS

Registry ID

205416

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

GLAXOSMITHKLINE INC

Start date

2021-04-15

Last update

2020-08-20

Conditions

• MENINGITIS B

Related clinical trials

• A PHASE 3B, OPEN LABEL, CONTROLLED, MULTI CENTER, EXTENSION STUDY TO ASSESS THE PERSISTENCE OF BACTERICIDAL ACTIVITY AT 4 TO 7.5 YEARS AFTER TWO DOSE PRIMARY SERIES OF NOVARTIS MENINGOCOCCAL B RECOMBINANT VACCINE AND THE RESPONSE TO A THIRD DOSE IN ADOLESCENTS AND YOUNG ADULT SUBJECTS WHO PREVIOUSLY PARTICIPATED IN PARENT STUDIES V72_41 AND V72PI0, COMPARED TO NAIVE HEALTHY CONTROLS
• "IMMUNOGENICITY AND SAFETY STUDY OF 1 AND 2 DOSES OF GSK BIOLOGICALS' MENINGOCOCCAL VACCINE GSK134612 IN TODDLERS, PERSISTANCE UP TO 5 YEARS AFTER VACCINATION AND CO-ADMINISTRATION WITH PFIZER'S PNEUMOCOCCAL VACCINE PREVENAR 13."

View on source registry